| Identification | Back Directory | [Name]
3-Quinolinecarboxylicacid, 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-,ethyl ester | [CAS]
158146-85-1 | [Synonyms]
3-Quinolinecarboxylicacid, 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1H-1,2,4-triazol-1-ylmethyl)-,ethyl ester | [Molecular Formula]
C25H26N4O6 | [MDL Number]
MFCD00932159 | [MOL File]
158146-85-1.mol | [Molecular Weight]
478.5 |
| Hazard Information | Back Directory | [Uses]
TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Thl-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis[1][2]. | [in vivo]
TAK-603 (6.25 mg/kg; p.o.; daily) reduces the Thl-type cytokine production both in the arthritic lesion and in the spleen[2]. | Animal Model: | AA rats[2] | | Dosage: | 6.25 mg/kg | | Administration: | P.o.; daily | | Result: | Inhibited arthritic paw swelling with the inhibition rate of 65% and the IFN-y mRNA expression in the arthritic joint was significantly reduced. |
| [References]
[1] Mizuno M, et al. Syntheses of metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603). Tetrahedron, 2006, 62(37), 8707–8714.
[2] Ohta Y, et al. TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis. Immunology. 1997 Sep;92(1):75-83. DOI:10.1046/j.1365-2567.1997.d01-2288.x |
|
|